As PD-L1 expression is enriched on the surface of tumor cells in patients with ESCC [11], Immune checkpoint inhibitors (ICIs) directed at PD-1 and its counterpart PD-L1 have displayed encouraging outcomes in the management of advanced ESCC. Here, CD274 is linked to neoplasm.